This paper examines the amount of variation among centres and estimates the overall e!ect of therapy in a multi-centre cancer clinical trial with censored failure time data. To investigate the centre e!ects, the variation in the treatment e!ect must be taken into consideration in addition to the var
Detecting treatment-by-centre interaction in multi-centre clinical trials
β Scribed by Richard F. Potthoff; Bercedis L. Peterson; Stephen L. George
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 144 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0277-6715
No coin nor oath required. For personal study only.
β¦ Synopsis
This paper considers several permutation tests for treatment-by-centre interaction in multi-centre clinical trials in which the endpoint is survival time subject to censoring. Some of the tests are based on existing tests and some are new. To evaluate and compare the tests with respect to power under different conditions, we generated survival times and censoring times through simulation. We used special methodology to handle the unusual problems that arise in power simulations when the tests under study are permutation tests. Different conditions yielded different interaction tests as the best performers. Although one test gave comparatively good power under almost all conditions, some of the other tests also appear to be useful. For the sample sizes and configurations in the simulations, power is generally low; thus it may not be possible to detect interaction reliably when it exists, a finding in agreement with the known low power for interaction tests in general.
π SIMILAR VOLUMES
When a clinical trial is conducted at more than one centre it is likely that the true treatment effect will not be identical at each centre. In other words there will be some degree of treatment-by-centre interaction. A number of alternative approaches for dealing with this have been suggested in th
In randomized clinical trials comparing treatment effects on diseases such as cancer, a multi-centre trial is usually conducted to accrue the required number of patients in a reasonable period of time. While we interpret the average treatment effect, it is necessary to examine the homogeneity of the
This paper considers an index to assess the success of blinding with application to a clinical trial of disulfiram. The index increases as the success of blinding increases, accounts for uncertain responses, and is scaled to an interval of 0 0 to 1.40-0 being complete lack of blinding and 1.0 being
## Abstract As its contribution to the 1960β64 clinical trial of the TNM Classification of breast cancer, The Ontario Cancer Treatment and Research Foundation reviewed in detail the distribution and 5βyear survival of 1,846 female patients classified according to TNM criteria. While further conside